Universal Sequencing Technology

Executive Summary

Universal Sequencing Technology (UST) is a privately held biotechnology company headquartered in Carlsbad, California, dedicated to democratizing next-generation sequencing (NGS) through innovative, accessible platforms. Founded in 2016, UST addresses critical limitations in current sequencing workflows with its flagship TELL-Seq technology, which enables short-read sequencers to produce ultra-long-range linked-read data—enhancing genome assembly, structural variant detection, and haplotype phasing without expensive long-read instruments. Complementing this is the AmpliDrop platform, a microfluidics-free single-cell sequencing solution that simplifies sample preparation and reduces costs, broadening access to single-cell genomics. By targeting key bottlenecks in throughput, accuracy, and affordability, UST positions itself as a disruptive force in the genomics tools market, serving researchers and clinical laboratories seeking scalable, high-resolution sequencing.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of AmpliDrop single-cell platform70% success
• Q3 2026Strategic partnership with major sequencing service provider60% success
• Q3 2026Series B funding round to scale manufacturing and sales75% success